@article{Roel G.W. Verhaak_Bas J. Wouters_Claudia A.J. Erpelinck_Saman Abbas_H. Berna Beverloo_Sanne Lugthart_Bob Löwenberg_Ruud Delwel_Peter J.M. Valk_2008, place={Pavia, Italy}, title={Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling}, volume={94}, url={https://haematologica.org/article/view/5128}, DOI={10.3324/haematol.13299}, abstractNote={We examined the gene expression profiles of two independent cohorts of patients with acute myeloid leukemia [n=247 and n=214 (younger than or equal to 60 years)] to study the applicability of gene expression profiling as a single assay in prediction of acute myeloid leukemia-specific molecular subtypes. The favorable cytogenetic acute myeloid leukemia subtypes, i.e., acute myeloid leukemia with t(8;21), t(15;17) or inv(16), were predicted with maximum accuracy (positive and negative predictive value: 100%). Mutations in <em>NPM1</em> and <em>CEBPA</em> were predicted less accurately (positive predictive value: 66% and 100%, and negative predictive value: 99% and 97% respectively). Various other characteristic molecular acute myeloid leukemia subtypes, i.e., mutant <em>FLT3</em> and <em>RAS</em&gt;, abnormalities involving 11q23, −5/5q-, −7/7q-, abnormalities involving 3q (abn3q) and t(9;22), could not be correctly predicted using gene expression profiling. In conclusion, gene expression profiling allows accurate prediction of certain acute myeloid leukemia subtypes, e.g. those characterized by expression of chimeric transcription factors. However, detection of mutations affecting signaling molecules and numerical abnormalities still requires alternative molecular methods.}, number={1}, journal={Haematologica}, author={Roel G.W. Verhaak and Bas J. Wouters and Claudia A.J. Erpelinck and Saman Abbas and H. Berna Beverloo and Sanne Lugthart and Bob Löwenberg and Ruud Delwel and Peter J.M. Valk}, year={2008}, month={Dec.}, pages={131-134} }